Anyone Buying Novartis
Q: if you guys are so sure that pix is gonna be approved by the FDA, are you buying novartis? Afterall, they are going to be the marketing arm of this drug if it makes it to the market?
A: The people on here could only buy 100 shares of Novartis. They are penny stock pumpers and dumers. Cant make money like that with $35/ share stocks. I have both CTIC and (Novartis) NVS at discount prices. NVS is still around it's lows right now so good time to get it before that starts to move. I think Novartis has just had bad luck with quite a few unsucessful trials this year and a stronger dollar hurting their bottom line. You reveal quite a poor level of intelligence with your comment. I've owned NVS since 2005 when I was getting an 88 cent dividend and accumulating more since getting back down in the $30s. Not everyone on this board, including the recent institutional investor, is a pumper and "dumer". Perhaps we're not as sophisticated as you, but a few speculative dollars on chemo reformulation, which may improve the lives of human beings suffering from cancer isn't such a bad thing. I assure you I will never see a short term 500% return on my money with NVS, but there's a chance with CTIC. Novartis and CTIC entered into a deal in 2006 for another drug, with rights to pixantrone thrown in as an afterthought. http://www.pharmaceutical-business-review.com/article_news.asp?guid=C... The royalties are relatively steep, and it would make more sense for an acquisition in some peoples opinions. See this one: http://www.iguanabio.com/cell-therapeutics-pixantrone-status/ Either way, that bodes well for those of us holding. The only real problem that i can see, would be if the FDA disapproves it. IMO, I would be surprised if that happens. There are quite a few people who suffer from MS that are waiting desperately for off-label use based upon a study in Italy ( i think?) As well as the toxicity benefits for people infected with non-Hodgkin's lymphoma. The standard chemo coctail for these people today is extrememly toxic to their heart. If it does get disapproved, look at LJPC. Click on their 3 month chart. Again, IMO, I think we see a stable $2 to $7 as we get closer to the end of Q4. IF all goes well. Even for someone who is in this long, you have to love those %'s in the short term as well. Always do your own DD. Personally, I bought more when it droped to . 31